For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

JEVTANA Trials Included mCRPC Patients With High-Disease Burden and Rapid Progression after Docetaxel1-4

JEVTANA 20 mg/m2 Dose Was Validated in the PROSELICA Trial3

Large, non-inferiority, multicenter, randomized, open-label study (N=1200)3

1200 patients with mCRPC who previously received docetaxel

Primary Endpoint: Median Overall Survival

Stratification:

ECOG PS: 0, 1 vs 2
Measurable vs nonmeasurable disease

JEVTANA
20 mg/m2

q3wks + prednisone (n=598)

JEVTANA
25 mg/m2

q3wks + prednisone (n=602)

ECOG: Eastern Cooperative Oncology Group

PROSELICA Included Patients With High-Disease Burden (n=1200)3

Disease Burden Presentation in PROSELICA trial: 31% visceral, 94% bone, and 49% lymph nodes

PROSELICA Patients Presented With Rapid Progression After Docetaxel (n=1200)3

86% of patients progressed during or within
6 months of last docetaxel dose. 25% of patients progressed during their last docetaxel infusion, 43% of patients progressed within 3 months since their last dose and 17% from 3-6 months since their last dose

View Summary of Demographics and Patient Characteristics3

JEVTANA 20 mg/m2 +
prednisone (n=598)
JEVTANA 25 mg/m2 +
prednisone (n=602)
Mean age, years (SD)
68.2 (7.2) 68.4 (7.8)
ECOG PS, No. (%)
0,1 539 (90.1) 540 (89.7)
2 59 (9.9) 62 (10.3)
PSA, ng/mL
Median 159.49 170.90
Progression diagnosis criteria, No. (%)
Progression diagnosis criteria, No. (%) 596 (99.7) 599 (94.5)
Increasing PSA 526 (88.0) 518 (86.0)
Progression of
measureable lesion
152 (25.4) 178 (29.6)
Progression of nonmeasureable
lesion (except bone)
66 (11.0) 72 (12.0)
Appearance of new
lesion on bone scan
145 (24.2) 141 (23.4)
Missing 2 (0.3) 3 (0.5)
Disease site (%)
Bone 93.5 94.5
Lymph nodes 49.2 49.7
Lung 15.6 15.9
Liver 15.7 15.0
Patients who experienced progression, No. (%)
During the last docetaxel treatment 153 (25.6) 154 (25.6)
< 3 months since last
docetaxel dose
251 (42) 270 (44.9)
3-6 months after last
docetaxel dose
110 (18.4) 96 (15.9)
>6 months since last
docetaxel dose
69 (11.5) 61 (10.1)
Missing 15 (2.5) 21 (3.5)
Time from last docetaxel dose to progression, months
Median (time) 1.0 1.0
Mean (SD) 2.7 (5.3) 2.3 (4.1)

JEVTANA is a NCCN designated Category 1 second-line therapy for mCRPC5 and has been prescribed to more than 30,000* patients.

*Estimate based on sales & use data in the U.S., 6/2010-8/2017. sanofi-aventis U.S. LLC, A SANOFI COMPANY.

Identify Appropriate Patient Types for JEVTANA

Hear Dr. Pachynski apply trial information to clinical practice and talk about appropriate patient types for JEVTANA.

Russell K. Pachynski, MD
Assistant Professor, Oncology Division
Washington University School of Medicine, in St. Louis, MO.

Video of Dr. Pachynski talking about identifying the appropriate patient types for JEVTANA

IMPORTANT SAFETY INFORMATION

WARNING: NEUTROPENIA AND HYPERSENSITIVITY

  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave jevtanapro.com


You are leaving jevtanapro.com to view another Sanofi Genzyme Corporation website.



Continue 
Cancel